Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ)
CNY12.48
+0.42 (+3.48%)
CN SHZ Healthcare Biotechnology
Address
No. 7 Jinyuan Road 400020
Chongqing, CN
Chongqing, CN
CEO
Lingfeng Jiang
Website
zhifeishengwu.com
IPO
2010-09-28
ISIN CNE100000V20
Description
Chongqing Zhifei Biological Products Co., Ltd. is a Chinese firm primarily engaged in the innovation, manufacturing, and commercialization of vaccines and other biological pharmaceuticals within the country. The company's establishment dates back to 2009, and its main operational base is located in Chongqing, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY12.48
+0.42 (+3.48%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
22M
Beta
1.29
Float Shares
1.60B
Free Float %
66.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.88% | -3.00% | -10.30% | -21.40% | -33.90% | -27.98% | -29.00% | -71.46% | -89.56% | +56.75% | +111.35% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
12.48
DCF (Levered)
6.79
-45.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
78% Bullish
| Rating | 2025-05 | Change |
|---|---|---|
| Strong Buy | 2 | -1 |
| Buy | 5 | -1 |
| Hold | 2 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
0.84
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-65.6% Q1'26: -9.4% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-832.1% Q1'26: -23.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-109.9% Q1'26: +8.2% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-191.8% Q1'26: -15.6% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-66.7% Q1'26: -4.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-0.1% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.74× Q1'26: -13.37× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 3 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
712.74M
est: 713.00M (0.0%)
|
445.95M
est: 600.00M (-25.7%)
|
1.34B
est: 1.26B (+6.6%)
|
5.23B
est: 5.22B (+0.1%)
|
10.59B
est: 10.59B (+0.0%)
|
15.19B
est: 15.20B (-0.1%)
|
30.65B
est: 28.09B (+9.1%)
|
38.26B
est: 34.73B (+10.2%)
|
52.92B
est: 46.73B (+13.2%)
|
26.07B
est: 28.27B (-7.8%)
|
8.96B
est: 25.70B (-65.1%)
|
25.77B
11.68B – 40.60B
+0.3% YoY
|
21.87B
9.91B – 34.45B
-15.1% YoY
|
| EBITDA |
231.49M
est: 170.02M (+36.2%)
|
65.31M
est: 143.08M (-54.4%)
|
553.93M
est: 300.44M (+84.4%)
|
1.80B
est: 1.25B (+44.9%)
|
2.95B
est: 2.52B (+17.0%)
|
4.13B
est: 3.63B (+14.0%)
|
12.30B
est: 6.70B (+83.6%)
|
9.00B
est: 8.28B (+8.7%)
|
9.52B
est: -745.14M (+1,377.3%)
|
2.71B
est: -450.73M (+701.3%)
|
-16.68B
est: -409.76M (-3,971.3%)
|
-410.90M
-647.38M – -186.30M
-0.3% YoY
|
-348.66M
-549.31M – -158.08M
+15.1% YoY
|
| EBIT |
190.75M
est: 163.14M (+16.9%)
|
11.11M
est: 137.29M (-91.9%)
|
493.24M
est: 288.28M (+71.1%)
|
1.72B
est: 1.19B (+43.9%)
|
2.87B
est: 2.42B (+18.3%)
|
4.01B
est: 3.48B (+15.3%)
|
11.92B
est: 6.43B (+85.6%)
|
8.70B
est: 7.95B (+9.4%)
|
9.21B
est: -1.12B (+920.8%)
|
2.34B
est: -678.48M (+444.6%)
|
-17.18B
est: -616.81M (-2,685.5%)
|
-618.52M
-974.49M – -280.44M
-0.3% YoY
|
-524.83M
-826.88M – -237.96M
+15.1% YoY
|
| Net Income |
197.40M
est: 199.60M (-1.1%)
|
32.52M
est: 79.84M (-59.3%)
|
432.28M
est: 437.54M (-1.2%)
|
1.45B
est: 1.46B (-0.9%)
|
2.37B
est: 2.30B (+3.1%)
|
3.30B
est: 3.38B (-2.4%)
|
10.21B
est: 8.66B (+17.9%)
|
7.54B
est: 8.07B (-6.6%)
|
8.07B
est: 6.04B (+33.5%)
|
2.02B
est: 2.53B (-20.1%)
|
-14.72B
est: 1.31B (-1,228.2%)
|
3.13B
888.64M – 5.37B
+139.7% YoY
|
2.83B
817.52M – 4.94B
-9.6% YoY
|
| SGA |
361.02M
est: 57.96M (+522.9%)
|
354.16M
est: 48.78M (+626.1%)
|
418.37M
est: 102.42M (+308.5%)
|
892.40M
est: 424.56M (+110.2%)
|
1.28B
est: 860.49M (+48.6%)
|
1.41B
est: 1.24B (+14.1%)
|
2.12B
est: 2.28B (-7.1%)
|
2.60B
est: 2.82B (-8.1%)
|
3.17B
est: 5.85B (-45.9%)
|
3.04B
est: 3.54B (-14.0%)
|
2.80B
est: 3.22B (-13.0%)
|
3.23B
1.46B – 5.08B
+0.3% YoY
|
2.74B
1.24B – 4.31B
-15.1% YoY
|
| EPS |
0.12
est: 0.08 (+44.0%)
|
0.02
est: 0.03 (-37.3%)
|
0.18
est: 0.18 (-1.5%)
|
0.60
est: 0.61 (-1.9%)
|
1.48
est: 0.96 (+54.4%)
|
1.38
est: 1.41 (-2.2%)
|
4.25
est: 3.61 (+17.6%)
|
3.14
est: 3.12 (+0.7%)
|
3.36
est: 2.52 (+33.3%)
|
0.84
est: 1.04 (-18.9%)
|
-6.15
est: 1.08 (-669.4%)
|
1.28
0.37 – 2.24
+18.8% YoY
|
1.18
0.34 – 2.06
-8.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-26 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-25 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-19 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-18 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-14 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
3.25B
OE per share TTM
1.36
Owner's Yield
9.99%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
15.9%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 126 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | KraneShares MSCI All China Health Care Index ETF KURE | 0.74% | 585.4K | 0.79% |
| 2 | VanEck ChiNext ETF CNXT | 0.20% | 248.5K | 0.65% |
| 3 | HSBC MSCI China A UCITS ETF HMCT.L | 0.12% | 164.1K | 0.30% |
| 4 | Samsung KODEX China CSI300 ETF 283580.KS | 0.07% | 141.3K | 0.12% |
| 5 | Xtrackers Harvest CSI 300 China A-Shares ETF ASHR | 0.06% | 818.1K | 0.65% |
| 6 | iShares MSCI China A UCITS ETF CNYE.MI | 0.06% | 59.5K | 0.45% |
| 7 | iShares MSCI China A UCITS ETF CNYA.L | 0.06% | 1.80M | 0.40% |
| 8 | Xtrackers Harvest CSI300 UCITS ETF 1D ASHR.L | 0.06% | 181.5K | 0.65% |
| 9 | Amundi MSCI China A UCITS ETF Acc CNAA.L | 0.06% | 80.3K | 0.35% |
| 10 | Xtrackers MSCI China A UCITS ETF 1C XX2D.L | 0.06% | 75.9K | 0.35% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-2.38M
Shares Outstanding
2.39B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Fei Qin | Vice President, Secretary of Board & Director | — | male |
| Jia Liu | Assistant to the President | — | female |
| Jie Shao | Vice President | — | male |
| Lingfeng Jiang | Vice Chairman of the Board & President | — | male |
| Rensheng Jiang | Chairman of the Board & Chief Executive Officer | — | male |
| Yu Zhang | Vice president | — | female |
| Zhang Jing | Vice President | — | female |
| Zhen Jing Li | Vice President, Chief Financial Officer & Director | — | male |
| Zhijun Wang | Chief Engineer | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300122.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
